Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
The latest announcement is out from Regeneron ( (REGN) ).
Regeneron presented significant business updates at the J.P. Morgan Healthcare Conference, highlighting progress across its clinical pipeline and market performance. The announcement included key advancements such as the expansion of Dupixent’s usage in treating chronic diseases, the continued leadership of EYLEA in the U.S. anti-VEGF category, and Libtayo’s groundbreaking results in high-risk cutaneous squamous cell carcinoma. Additionally, Regeneron’s pipeline is poised for future growth with promising candidates targeting a commercial market expected to exceed $220 billion by 2030, underscoring its strategic positioning in the industry.
More about Regeneron
Regeneron Pharmaceuticals, Inc. operates in the biotechnology industry, specializing in the development of innovative medicines for serious diseases. The company is known for its robust research and development capabilities, focusing on a wide array of therapeutic areas including ophthalmology, immunology, and oncology. Regeneron’s marketed products include Dupixent, EYLEA, and Libtayo, which are leaders in their respective fields, reflecting the company’s strong market presence and commitment to addressing unmet medical needs.
YTD Price Performance: -2.56%
Average Trading Volume: 832,286
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $76.58B
Find detailed analytics on REGN stock on TipRanks’ Stock Analysis page.
